<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863010</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1309</article-id><article-id pub-id-type="other">EPV0656</article-id><article-id pub-id-type="pii">S0924933824013099</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Use of vortioxetine in treating obsessive-compulsive disorder: a case report</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Jim&#x000e9;nez-Fern&#x000e1;ndez</surname><given-names>B.</given-names></name><xref rid="aff2919" ref-type="aff"/><xref rid="cor1161" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Motta-Rojas</surname><given-names>N. V.</given-names></name><xref rid="aff2919" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Iborra-Vicheto</surname><given-names>X.</given-names></name><xref rid="aff2919" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Cuevas-Esteban</surname><given-names>J.</given-names></name><xref rid="aff2919" ref-type="aff"/></contrib></contrib-group><aff id="aff2919">
Psychiatry, <institution>Hospital Universitari Germans Trias i Pujol</institution>, <city>Badalona</city>, <country>Spain</country></aff><author-notes><corresp id="cor1161"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1284">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S632</fpage><lpage>S632</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824013099a.pdf"/><abstract><sec id="sec6979"><title>Introduction</title><p>
Obsessive-compulsive disorder (OCD) is a chronic disorder with a wide range of manifestations but primarily intrusive thoughts (obsessions) and/or ritualized actions (compulsions) that can cause a huge distress in patients&#x02019; life. First-line treatment for OCD are selective serotonin reuptake inhibitors (SSRIs). Tricyclic antidepressants are used as second-line treatment due to secondary effects. Also antipsychotics such as aripiprazole are approved for treating OCD. Vortioxetine is has 5-HT3, 5-HT7 and 5-HT1D antagonists, 5-HT1B partial agonist and a 5-HT1A agonist and serotonin transporter inhibitor property. It is used in major depressive and anxiety disorders. A male 48 years old patient with an OCD diagnosis since he was 21, was reffered to psychiatry department. Previously, he had no response with SSRIs at full dosage and clomipramine 75mg was effective. At 46 years old, he had an acute myocardial infarction. He also admited not taking the medication regularly due to sexual disfunction and having affective symptoms related to the distress caused by OCD.</p></sec><sec id="sec6980"><title>Objectives</title><p>To evaluate efficacy of vortioxetine in treating OCD in a patient with contraindications for tricyclic antidepressants and no response to SSRIs.</p></sec><sec id="sec6981"><title>Methods</title><p>Clomipramine dose was reduced until discontinuation. After one week without treatment, basal scores for Hamilton Scale and Dimensional&#x000a0;Yale-Brown Obsessive-Compulsive Scale (DY-BOCS) were collected. Same data was collected again after 10 weeks treatment.</p></sec><sec id="sec6982"><title>Results</title><p>The dosage of vortioxetine was progressively titrated until 20mg daily in 3 weeks lapse. Diazepam 5mg was added in case of insomnia or anxiety. Aripiprazole 5mg was added in the third week of treatment as adjunctive treatment due to the recurrence of some intrusive thoughts (discontinued by himself because of akathisia). Finally, the patient reported an improvement in affective and OCD symptoms in the sixth week of treatment that was sustained until the tenth week, when data was recollected. The patient did not refer sexual disfunction.</p><p>The pre and post results are summarized in tables 1 and 2.<table-wrap position="anchor" id="tab34"><label>
Table 1.</label><caption><p>Hamilton Depresion Rating Scale (0-52)</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/></colgroup><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Basal</th><th align="left" valign="middle" rowspan="1" colspan="1">Post 10-week treatment</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr></tbody></table><graphic xlink:href="S0924933824013099-TABU0034" position="anchor"/></alternatives></table-wrap></p><p>Dimensional Y-BOCS (0-15)<table-wrap position="anchor" id="tab35"><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" valign="middle" rowspan="1" colspan="1">Basal</th><th align="center" valign="middle" rowspan="1" colspan="1">Post 10-week treatment</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Aggressive-related obsessions and compulsions</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Religious-related obsessions and compulsions</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Symmetry and order</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pollution and cleaning</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Collecting and accumulation</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Miscellaneous</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td></tr></tbody></table><graphic xlink:href="S0924933824013099-TABU0035" position="anchor"/></alternatives></table-wrap>
</p></sec><sec id="sec6983"><title>Conclusions</title><p>Vortioxetine might be a promising molecule for treating OCD in patients with contraindications for first and second-line treatments.</p></sec><sec id="sec6984"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>